ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Ironwood Pharmaceuticals, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 1.99 times
2
The company has declared positive results in Jan 70 after 8 consecutive negative quarters
- RAW MATERIAL COST(Y) Fallen by -0.16% (YoY)
- NET SALES(Q) Highest at USD 122.06 MM
- OPERATING PROFIT(Q) Highest at USD 78.16 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 104.03%, its profits have risen by 515.6% ; the PEG ratio of the company is 0
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Market Beating Performance
- The stock has generated a return of 104.03% in the last 1 year, much higher than market (S&P 500) returns of 13.68%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Ironwood Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ironwood Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ironwood Pharmaceuticals, Inc.
114.09%
-0.44
120.64%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-3.21%
EBIT Growth (5y)
0.44%
EBIT to Interest (avg)
12.02
Debt to EBITDA (avg)
1.99
Net Debt to Equity (avg)
-1.43
Sales to Capital Employed (avg)
1.17
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
82.56%
ROE (avg)
67.93%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
-2.08
EV to EBIT
6.85
EV to EBITDA
6.76
EV to Capital Employed
5.44
EV to Sales
2.94
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
79.43%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend27What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -0.16% (YoY
NET SALES(Q)
Highest at USD 122.06 MM
OPERATING PROFIT(Q)
Highest at USD 78.16 MM
OPERATING PROFIT MARGIN(Q)
Highest at 64.03 %
PRE-TAX PROFIT(Q)
Highest at USD 70.22 MM
NET PROFIT(Q)
Highest at USD 41.38 MM
EPS(Q)
Highest at USD 0.23
-4What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD 67.67 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.45 times
Here's what is working for Ironwood Pharmaceuticals, Inc.
Pre-Tax Profit
At USD 70.22 MM has Grown at 296.18%
over average net sales of the previous four periods of USD 17.72 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 41.38 MM has Grown at 1,149.29%
over average net sales of the previous four periods of USD 3.31 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 122.06 MM has Grown at 58.25%
over average net sales of the previous four periods of USD 77.13 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
Highest at USD 122.06 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 78.16 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 64.03 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 70.22 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 41.38 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.23
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -0.16% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Ironwood Pharmaceuticals, Inc.
Operating Cash Flow
Lowest at USD 67.67 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Debtors Turnover Ratio
Lowest at 3.45 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
